Bictegravir 1611493-60-7

Description:

API Nomen Indicium Innovator Exitus patentibus Date (US)
Bictegravir 1611493-60-7 HIV-1 infectio Gilead Sciences 19 Dec


Product Detail

Product Tags

Product SINGULA

Descriptio

Bictegravir nova est, potens inhibitor HIV-1 integrae cum IC50 7.5 nm.

In vitro

Bictegravir (BIC) vetat activitatem in acia transferre cum IC50 inter 7.5± 0.3 nM.Relativum ad suum inhibitionis trans- litus activitatem, Bictegravir multo debilior est inhibitor of 3.-processing actio HIV-I IN, cum IC50 de CCXLI±51 nM.Bictegravir auget cumulum 2-LTR circulorum ~5-plicarum relativum ad ludibrium tractatum imperium et quantitatem productorum integrationis authenticae in cellulis infectis per 100-duplicem reducit.Bictegravir potenter vetat replicationem HIV-1 in utraque MT-2 et MT-4 cellularum cum EC50s 1.5 et 2.4 nM, respective.Bictegravir effectus antivirales potentes exhibet lymphocytes tum primarios CD4+ T et macrophages monocyto-ectae, cum EC50s 1.5.±0.3 nM et 6.6 "±4.1 nM, respective, quae cum valoribus in lineis T-cellulis habitis comparantur[1].

MCE independenter subtilitatem horum methodorum non confirmavit.Tantum referendi sunt.

NCT Number Sponsor Conditio Satus Date

Phase

NCT03998176 Universitas Nebraska|Gilead Sciences HIV-1-infectio October 9, 2019

Phase 4

NCT03789968 Thomas Jefferson University|University of Maryland, College Park|University of Maryland, University Health | HIV+AIDS Septembris 1, 2019
NCT04249037 University of Colorado, Denver|Gilead Sciences HIV+AIDS Martii 1, 2020

Non pertinet

NCT04132674 Vancuverium morbis infectivis Centre Humana immunitas Virus I Infectio|Drug Use November 26, 2018

Phase 4

NCT04054089 Cristina Mussini Universitas Mutinensis et Regii Lepidi HIV Infectiones September 2019

Phase 4

NCT04155554 Azienda Ospedaliera Universitaria Senese | Catholic University of the Holy Heart | Ospedale Policlinico San Martino | HIV-1-infectio Die 29 Ianuarii, 2020

Phase 3

NCT02275065 Gilead Sciences HIV-1 Infectio October 2014

Phase 1

NCT03711253 Universitas Southern California Acute HIV Infectio October 14, 2019

Phase 4

NCT02400307 Gilead Sciences HIV April 17, 2015

Phase 1

NCT03499483 Fenway Community Health HIV Prevention Die 24 mensis Ianuarii, 2019

Phase 4

NCT03502005 Mediterranei Research Group, Inc.|Gilead Sciences De Viris Illustribus Humanis Martii 1, 2018

Phase 4

Chemical structure

Bictegravir-1611493-60-7

CERTIFICATE

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

QUALITY MANAGEMENT

Quality management1

Rogatio18Qualitas Constantia Aestimatio inceptis quae probaverunt4, et6incepta approbantes.

Quality management2

Provectus qualitas internationalis administrandi ratio solidum fundamentum venditio posuit.

Quality management3

Qualitas vigilantia percurrit totum vitae cyclum producti, ut qualitatem et therapeuticum effectum curet.

Quality management4

Negotiis professionalibus regularibus turmas sustinet qualitatem postulatorum in applicatione et adnotatione.

PROLATIO MAGISTERIUM

cpf5
cpf6

Korea Countec Bottled Packaging linea

cpf7
cpf8

Taiwan CVC Bottled Packaging Line

cpf9
cpf10

Italia CAM Board Packaging Line

cpf11

German Fette Compacting Machine

cpf12

Iaponia Viswill Traba Detector

cpf14-1

DCS Control Room

SOCIUS

Cooperatio internationalis
International cooperation
Cooperatio domestica
Domestic cooperation

  • Previous:
  • Deinde:

  • Epistulam tuam hic scribe et mitte nobis

    Products categories